Option-to-acquire deals remain rare in biotech's buzzy M&A season
Two recent deals are focusing attention on a relatively rare structure for biotech buyouts: the option-to-acquire. Drug developers are on pace to have one of the best dealmaking years in industry history, with more than ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.